*Correspondence Author:
Zhi-Chun Gu, MD, Department of
Pharmacy, Renji Hospital, School of Medicine, Shanghai Jiao Tong
University, Shanghai 200127, China.
E-mail:
guzhichun213@163.com
Abstract
Aim
The population included in randomized controlled clinical trial of
ROCKET AF and observational studies were different, and the
effectiveness and safety of rivaroxaban in stroke prevention of atrial
fibrillation (AF) varied among studies. The aim of this study was to
estimate the real-world outcomes of rivaroxaban in AF patients in a
relatively accurate way.